Anal cancer’s first randomized trial for inoperable disease sets the treatment standard

Results from first randomized trial for inoperable anal cancer suggest that carboplatin-paclitaxel become the standard treatment for these patients. Results of worldwide InterAAct trial published in the Journal of Clinical Oncology. Phase 2 trial compared two conventional chemotherapies (N=91). Objective response rate (the primary endpoint) the same between treatments: 57% (cisplatin-5FU) versus 59% (carboplatin-paclitaxel). More adverse events with cisplatin-5FU: 62% versus 36%. Improved overall survival with carboplatin-paclitaxel (20 months versus 12.3).